Dr. Spira on the Impact of the PACIFIC-R Trial in Unresectable Stage III NSCLC

Video

Alexander I. Spira, MD, PhD, FACP, discusses the impact of the PACIFIC-R trial in patients with unresectable stage III non–small cell lung cancer.

Alexander I. Spira, MD, PhD, FACP, medical oncologist, director, Virginia Cancer Specialists Research Institute and Phase 1 Trial Program, Virginia Cancer Specialists, discusses the impact of the PACIFIC-R trial (NCT03798535) in patients with unresectable stage III non–small cell lung cancer (NSCLC).

The real-world data generated from the PACIFIC-R trial, which were presented during the 2021 ESMO Congress, indicated that the median progression-free survival with durvalumab (Imfinizi) was higher compared with that observed in the durvalumab arm of the phase 3 PACIFIC trial (NCT02125461) in patients with unresectable stage III NSCLC. However, challenges associated with real-world data collection suggest that the benefit observed could be overestimated.

Ultimately, the findings support the use of durvalumab in this patient population; however, they will likely not increase the uptake of durvalumab in the clinical setting, Spira says. Although the goal is for all eligible patients to receive durvalumab when indicated, some patients cannot receive the agent because of toxicity or logistical hurdles, Spira explains. Additional data are needed to provide further insight into the real-world utility of durvalumab in this patient population, Spira concludes.

This activity is funded in part by Daiichi Sankyo. Content independently produced by OncLive.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD